Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety and PK of single-dose tecarfarin in healthy Chinese volunteers
NCT03652779Phase 1Completed
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Jun 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tecarfarin in thromboembolism and Atrial fibrillation (AFib) (4 arms), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoints: Adverse Events Frequency at 15 Days and Adverse Events Severity at 15 Days. Started Jun 2018; status: completed.
02
Drugs
tecarfarin
03
Conditions
thromboembolismAtrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03652779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652779.